TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27267689
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose beetroot juice (H-BT; 250 ml, n=10)
Study: 27267689
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose beetroot juice (L-BT; 125 ml, n=9)
Study: 27267689
Drug: Isocaloric placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric placebo (PLA; 250 ml, n=10)
Study: 25881059
Drug: SMS-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS-based intervention for treatment adherence
Study: 21957667
Drug: Salovum egg
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salovum egg yolk powder plus standard treatment
Study: 19661012
Drug: metoprolol XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol XL 25 mg/chlorthalidone 6.25 mg
Study: 19661012
Drug: metoprolol XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol XL 50 mg/chlorthalidone 12.5 mg
Study: 19661012
Drug: metoprolol XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol XL 25 mg/HCTZ 12.5 mg
Study: 19661012
Drug: metoprolol XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol XL 50 mg/HCTZ 12.5 mg
Study: 16935462
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no L-thyroxine treatment)
Study: 1390955
Drug: Haloperidol or
Normalized name: haloperidol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol or perazine (neuroleptic drugs)
Study: 3909331
Drug: Aztreonam (1‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam (1‐2 g administered intravenously three or four times daily)
Study: 3909331
Drug: Tobramycin (3‐5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin (3‐5 mg/kg per day)
Study: 29339395
Drug: Finafloxacin 800
Normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Finafloxacin 800 mg once a day for 5 days (FINA05)
Study: 29339395
Drug: Finafloxacin 800
Normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Finafloxacin 800 mg once a day for 10 days (FINA10)
Study: 29339395
Drug: Ciprofloxacin 400
Normalized name: ciprofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 400 mg/500 mg twice a day for 10 days (CIPRO10)
Study: 27575452
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion (CEI) with thoracic epidural levobupivacaine 0.12% plus sufentanil 0.4 µg/mL for 48 hours
Study: 27575452
Drug: Wound infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound infiltration and continuous infusion with local anesthetics plus a single morphine bolus (CWI‐M) with 10 mL levobupivacaine 0.5% and levobupivacaine 0.25% infusion for 48 hours
Study: 18375319
Drug: Intracoronary nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary nicardipine (1 mL, 0.1 mg)
Study: 18375319
Drug: NaCl (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl (1 mL)
Study: 11493736
Drug: G‐‐CSF plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐‐CSF plus dexamethasone
Study: 11493736
Drug: G‐‐CSF alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐‐CSF alone
Study: 2975227
Drug: Indobufen 200
Normalized name: indobufen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen 200 mg
Study: 31785250
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg of nalbuphine
Study: 31785250
Drug: 2.5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 μg/kg of sufentanil
Study: 29952216
Drug: ENABLE CHF-PC
Normalized name: Enablex
DrugBank: Darifenacin (DB00496)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ENABLE CHF-PC intervention (in-person palliative care assessment, weekly telehealth coaching sessions, monthly follow-up)
Study: 26043228
Drug: GLP-1 RA
Normalized name: RAS
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GLP-1 RA liraglutide (1.2 mg/d) for 52 weeks
Study: 26043228
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no GLP-1 RA treatment)
Study: 21641776
Drug: Adjunctive armodafinil
Normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive armodafinil (150 mg/d)
Study: 17012108
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 (45 mg daily)
Study: 17012108
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 (45 mg daily) plus Vitamin D3 (0.75 microg 1alpha‐hydroxyvitamin D3 daily)
Study: 15271700
Drug: Rapid infusion
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid infusion of 500 mL of a gelatin solution
Study: 10669675
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by radiation therapy (60 Gy at 2.0 Gy per fraction)
Study: 10669675
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation (1.2 Gy per fraction delivered twice daily to a total dose of 69.6 Gy)
Study: 9193736
Drug: m‐CPP (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: m‐CPP (0.25 mg/kg body weight)
Study: 8437010
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg dextromethorphan daily for 12 weeks
Study: 8437010
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg dextromethorphan daily for up to 6 months
Study: 30686699
Drug: Azithromycin (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1,000 mg before LTx and 250 mg every other day from Day 1 to Day 31 after LTx)
Study: 28606190
Drug: Public reporting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Public reporting of prescription indicators monthly for one year
Study: 21172721
Drug: AZD0837 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0837 150 mg
Study: 21172721
Drug: AZD0837 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0837 300 mg
Study: 21172721
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (no treatment, aspirin 75‐325 mg or clopidogrel 75 mg once daily)
Study: 21172721
Drug: AZD0837 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0837 150 mg and 300 mg
Study: 14742786
Drug: High-dose amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose amoxicillin (80-90 mg/kg/d)
Study: 14742786
Drug: Standard-dose amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose amoxicillin (40-45 mg/kg/d)
Study: 11275035
Drug: Intravaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal misoprostol (50 microg tablet every 4 hours for a maximum of six doses)
Study: 11275035
Drug: Transcervical Foley
Normalized name: CATHETER,FOLEY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcervical Foley catheter (30‐mL Foley catheter placed transcervically with maintenance of traction)
Study: 2420386
Drug: Dioctyl sodium
Normalized name: Dioctyl sodium sulfosuccinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dioctyl sodium sulfosuccinate (DS) administered 30 minutes before tetracycline and on -3, -2, and -1 day in the evening before tetracycline administration
Study: 2420386
Drug: Tetracycline products
Normalized name: tetracycline Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline products (fast dissolving capsule, slow dissolving capsule, and suspension) without DS
Study: 27405724
Drug: Promotion group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promotion group (weekly emailed tips emphasizing social network interactions for walking)
Study: 27405724
Drug: Activity group
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity group (weekly tips + evidence‐based online fitness walking intervention)
Study: 27405724
Drug: Social Networks
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social Networks group (weekly tips + online networking site for walking)
Study: 24786143
Drug: High-potency statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-potency statin regimen (simvastatin 40 mg/day for 1 month, then simvastatin 80 mg/day)
Study: 24786143
Drug: Delayed moderate-potency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed moderate-potency statin strategy (placebo for 4 months, then simvastatin 20 mg/day)
Study: 19652922
Drug: Iron-supplemented group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-supplemented group (ISG) received 150 mg ferrous sulfate once weekly for 16 weeks.
Study: 18813039
Drug: 2.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg/kg propofol plus 1.5 microg/kg remifentanil
Study: 18813039
Drug: 4.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 mg/kg propofol plus 0.5 microg/kg remifentanil
Study: 12947367
Drug: PEG-Sak at
Normalized name: AT-7519
DrugBank: AT-7519 (DB08142)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-Sak at 0.01 mg/kg
Study: 12947367
Drug: PEG-Sak at
Normalized name: AT-7519
DrugBank: AT-7519 (DB08142)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-Sak at doses of 0.01875 to 0.0375 mg/kg (n = 314)
Study: 12947367
Drug: PEG-Sak at
Normalized name: AT-7519
DrugBank: AT-7519 (DB08142)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-Sak at 0.05 mg/kg (n = 23)
Study: 6352036
Drug: Propranolol-hydralazine combination
Normalized name: dihydralazine / propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol-hydralazine combination (40 mg/25 mg, 80 mg/25 mg, 80 mg/50 mg, 120 mg/50 mg, 160 mg/50 mg, 160 mg/100 mg)
Study: 6352036
Drug: Propranolol-hydralazine combination
Normalized name: dihydralazine / propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol-hydralazine combination
Study: 16521849
Drug: Ribose (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribose (3 g ribose + 150 microg folate)
Study: 16521849
Drug: Placebo (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (150 mL)
Study: 10919421
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion
Study: 10520911
Drug: Paravertebral infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paravertebral infusion
Study: 1778538
Drug: Sustained-release acebutolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release acebutolol (500 mg/day)
Study: 1778538
Drug: Conventional acebutolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional acebutolol (200 mg tid)
Study: 30707227
Drug: Thyrotropin suppression
Normalized name: Thyrotropin
DrugBank: Thyrotropin (DB15263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin suppression through levothyroxine therapy
Study: 21931661
Drug: Aprepitant 125
Normalized name: aprepitant 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 125 mg QD (Low)
Study: 21931661
Drug: Aprepitant 250
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant 250 mg QD (High)
Study: 17329466
Drug: Olanzapine (7.5-30.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (7.5-30.0 mg/day)
Study: 10930903
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg daily plus amoxycillin 1 g b.d. and clarithromycin 250 mg b.d. for 1 week (Group PAC)
Study: 10930903
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg daily for 1 month (Group P)
Study: 9207754
Drug: Low-dose Convit
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Convit vaccine plus MDT
Study: 9207754
Drug: Killed Mycobacterium
Normalized name: Heat Killed Mycobacterium W Immunomodulator
DrugBank: Mycobacterium w. Vaccine (DB15798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed Mycobacterium leprae vaccine plus MDT
Study: 1539776
Drug: omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 40 mg 12 hourly alone
Study: 1539776
Drug: omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 40 mg 12 hourly with sodium citrate
Study: 1539776
Drug: ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranitidine 150 mg 6 hourly with sodium citrate
Study: 26894485
Drug: loratadine 10
Normalized name: loratadine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: loratadine 10 mg daily for 7 days
Study: 18091289
Drug: Telephone-only motivational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-only motivational interviewing (MI) intervention with a pedometer and monthly MI telephone calls over 6 months
Study: 15939582
Drug: Zileuton (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zileuton (600 mg) four times a day for 5 days
Study: 11074181
Drug: Levetiracetam 1000
Normalized name: levetiracetam 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam 1000 mg per day
Study: 11074181
Drug: Levetiracetam 2000
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam 2000 mg per day
Study: 11074181
Drug: Levetiracetam 3000
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam 3000 mg per day
Study: 11074181
Drug: Levetiracetam 4000
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam 4000 mg per day
Study: 11074181
Drug: Levetiracetam (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (any dose)
Study: 9004249
Drug: NG‐nitro‐L‐arginine methyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG‐nitro‐L‐arginine methyl ester (L‐NAME) 40 micrograms/kg injected plus 50 micrograms/kg infused over 60 min
Study: 9004249
Drug: NG‐nitro‐L‐arginine methyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG‐nitro‐L‐arginine methyl ester (L‐NAME)
Study: 1627424
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (cyclophosphamide, methotrexate, fluorouracil, and prednisone for six cycles)
Study: 7458118
Drug: Cephalozoline administered
Normalized name: cephaloridine
DrugBank: Cefaloridine (DB09008)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalozoline administered 1 hour before and 5 and 12 hours after surgery
Study: 7458118
Drug: Thiamphenicol administered
Normalized name: thiamphenicol
DrugBank: Thiamphenicol (DB08621)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamphenicol administered 1 hour before and 5 and 12 hours after surgery
Study: 7458118
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cephalozoline and thiamphenicol administered 1 hour before and 5 and 12 hours after surgery
Study: 7458118
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics administered (control group)
Study: 22674156
Drug: Intravenous butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous butorphanol
Study: 24021297
Drug: Formula-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula-based dosing of Genotropin® GH (0.18 to 0.7 mg/kg/week)
Study: 24021297
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing of Genotropin® (0.37 mg/kg/week)
Study: 20844485
Drug: Omeprazole (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (80 mg) with clopidogrel (300 mg loading dose/75 mg/day maintenance dose)
Study: 20844485
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading dose/75 mg/day maintenance dose) administered 12 hours apart from omeprazole (80 mg)
Study: 20844485
Drug: Clopidogrel (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600 mg loading dose/150 mg/day maintenance dose) with omeprazole (80 mg)
Study: 20844485
Drug: Pantoprazole (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (80 mg) with clopidogrel (300 mg loading dose/75 mg/day maintenance dose)
Study: 16918592
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (IDet) 0.3 U/kg
Study: 16918592
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (IDet) 0.6 U/kg
Study: 16918592
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (IDet) 1.2 U/kg
Study: 16918592
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin 0.3 IU/kg
Study: 16918592
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin 0.6 IU/kg
Study: 16918592
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin 1.2 IU/kg
Study: 7481865
Drug: Various adjuvant
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various adjuvant treatments
Study: 17434599
Drug: Mood stabilizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mood stabilizer treatment
Study: 20834185
Drug: Low-dose Erythropoietin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Erythropoietin (6,000 IU during PCI, 24h and 48h)
Study: 15803314
Drug: Perindopril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (2 mg/day; n = 20)
Study: 15803314
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mg/day; n = 20)
Study: 10329810
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 25 micrograms to 500 micrograms, twice daily
Study: 7851579
Drug: Oral 17
Normalized name: polyoxypropylene (17)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 17 beta-E2 with high dose of CPA
Study: 7851579
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 beta-E2 with high dose of CPA
Study: 7015912
Drug: Budesonide (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (topical corticosteroid)
Study: 31848231
Drug: Immediate disease-modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate disease-modifying therapy (DMT)
Study: 31848231
Drug: Delayed disease-modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed disease-modifying therapy (DMT)
Study: 28640124
Drug: Anesthesia machine:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia machine: Excel, Avance, Cato, Primus with low-flow anesthesia (0.5, 1, and 4 L/min)
Study: 28640124
Drug: Anesthesia machine:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia machine: Cato and Primus with fresh gas flow of 4 L/min
Study: 24007540
Drug: Birth Preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birth Preparation Program (BPP)
Study: 18704426
Drug: rhTNFR:Fc (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhTNFR:Fc (25 mg, subcutaneous injection, twice weekly)
Study: 3529677
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (daily dose 400 I.E. d‐alpha‐tocopherylacetate)
Study: 31026298
Drug: Social and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social and preventive medicine consultation (intervention group)
Study: 28760534
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with standardized Japanese cedar pollen extract
Study: 26991399
Drug: vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: vonoprazan 20 mg twice daily (b.d.)
Study: 26991399
Drug: vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: vonoprazan 20 mg daily
Study: 26991399
Drug: esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: esomeprazole 20 mg b.d.
Study: 26991399
Drug: esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: esomeprazole 20 mg daily
Study: 20096622
Drug: Liposomal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal spray
Study: 18671464
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment options including surgery, radiotherapy, and systemic chemotherapy.
Study: 15972867
Drug: Standard 24-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 24-week regimen of peginterferon alfa-2b at a dose of 1.0 mug per kilogram weekly plus ribavirin at a dose of 1000 mg or 1200 mg daily.
Study: 8765493
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylprednisolone (HDMP) treatment, 30 mg/kg orally for 4 days
Study: 8765493
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylprednisolone (HDMP) treatment
Study: 8765493
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no HDMP treatment)
Study: 1532974
Drug: Single drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drug therapy for maintenance of remission
Study: 25670541
Drug: C-HART (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-HART (30 Gy/2 Gy daily followed by twice-daily 1.4 Gy to a total of 70.6 Gy with concurrent mitomycin C/5-FU)
Study: 25670541
Drug: HART (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: HART (16 Gy/2 Gy daily followed by twice-daily 1.4 Gy to a total dose of 77.6 Gy alone)
Study: 22077535
Drug: Self-report administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-report administration of the Post-Concussion Scale